Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors’ advantages, the patients’ therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classifi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Liao, Wen-Ling, Lee, Wen-Jane, Chen, Ching-Chu, Lu, Chieh Hsiang, Chen, Chien-Hsiun, Chou, Yi-Chun, Lee, I-Te, Sheu, Wayne H-H, Wu, Jer-Yuarn, Yang, Chi-Fan, Wang, Chung-Hsing, Tsai, Fuu-Jen
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5392306/
https://ncbi.nlm.nih.gov/pubmed/28160554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14951
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires